Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.

Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM; Cancer Prevention Network.

J Clin Pharmacol. 2013 Apr;53(4):403-12. doi: 10.1002/jcph.26. Epub 2013 Feb 22.

2.

Randomized phase II trial of sulindac for lung cancer chemoprevention.

Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J; Cancer Prevention Network.

Lung Cancer. 2013 Mar;79(3):254-61. doi: 10.1016/j.lungcan.2012.11.011. Epub 2012 Dec 20.

3.

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network.

Gastroenterology. 2012 Oct;143(4):917-26.e1. doi: 10.1053/j.gastro.2012.06.044. Epub 2012 Jul 11.

4.

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P.

Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22.

5.

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.

6.

Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Feb;4(2):259-69. doi: 10.1158/1940-6207.CAPR-10-0215. Epub 2011 Jan 5.

7.

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA.

J Thorac Oncol. 2010 Sep;5(9):1346-53. doi: 10.1097/JTO.0b013e3181ec18c4.

8.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG.

J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.

9.

Supplemental Content

Loading ...
Support Center